O
Ofer Lavie
Researcher at Technion – Israel Institute of Technology
Publications - 199
Citations - 3925
Ofer Lavie is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Endometrial cancer & Cancer. The author has an hindex of 33, co-authored 171 publications receiving 3412 citations. Previous affiliations of Ofer Lavie include Ben-Gurion University of the Negev & Rappaport Faculty of Medicine.
Papers
More filters
Journal ArticleDOI
Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma.
TL;DR: It is demonstrated for the first time that increased numbers of CTLs at the invasive border may be a reliable independent prognostic factor of survival in patients with endometrial carcinoma.
Journal ArticleDOI
Robotic-assisted laparoscopic myomectomy compared with standard laparoscopic myomectomy—a retrospective matched control study
TL;DR: It appears that in the hands of a skilled laparoscopic surgeon, the RALM does not offer any major advantage and this technology, however, offers exciting potential applications while learning endoscopic surgery.
Journal ArticleDOI
Dynamic Nanoparticle-Based Flexible Sensors: Diagnosis of Ovarian Carcinoma from Exhaled Breath.
TL;DR: Strain-related response successfully discriminated between exhaled breath collected from control subjects and those with ovarian cancer, with data from a single sensor being sufficient to obtain 82% accuracy, irrespective of important confounding factors, such as tobacco consumption and comorbidities.
Journal ArticleDOI
Low-grade serous ovarian cancer: A review.
TL;DR: Studies of the mitogen-activated protein kinase (MAPK) inhibitor in low-grade serous ovarian cancer suggest that identifying MAPK mutations might eventually be useful in guiding treatment, and is superior to more detailed grading systems in terms of predicting survival.
Journal Article
Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
TL;DR: Cancer-testis antigen expression in ovarian serous neoplasms correlates directly with their degree of malignancy, and MAGE-A4 expression, and to a lesser degree NY-ESO-1 expression, is characteristic of the majority of serous carcinomas.